The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1759
July 20, 2026
View Complete Issue         Table of Contents 2019 
Omidenepag Isopropyl (Omlonti) for Glaucoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Omidenepag Isopropyl (Omlonti) for Glaucoma
July 20, 2026 (Issue: 1759)
The FDA has approved Omlonti (Ocuvex), a 0.002% ophthalmic solution of the prostaglandin EP2 receptor agonist omidenepag isopropyl, for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension....more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Omidenepag Isopropyl (Omlonti) for Glaucoma
Article code: 1759b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.